Valeant continues derma buyout streak
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticalsis to fortify its dermatology business with the $285 million acquisition of Dow Pharmaceutical Sciences. The privately-held company will boost Valeant's US dermatology franchise with a complementary pipeline and revenue-generating contract service business.